Lead program IMG-007 is a first-in-class, non-T cell-depleting anti-OX40 receptor antagonist with extended half-life, signaling a differentiated immunology asset with potential across autoimmune and inflammatory diseases, presenting a high-value partnering or licensing opportunity.

Clinical progress Phase 2b trial in moderate-to-severe atopic dermatitis underway, with prior Phase 1b/2a data in atopic dermatitis and alopecia areata, creating near-term engagement potential with pharma companies seeking late-stage or near-term data for MAA/label expansion discussions.

Financial readiness Recent private placement secured approximately $30 million in new funding, and the company reports quarterly results alongside a broader funding runway, indicating readiness for strategic collaborations, co-development deals, or potential in-licensing discussions.

Strategic visibility Active participation in major conferences (Jefferies Global Healthcare Conference) and public company disclosures, offering timely touchpoints for BD outreach, investor/partner interest, and visibility to potential collaborators evaluating pipeline Synergy.

Supportive ecosystem Existing investor syndicate includes Omega Funds and OrbiMed with additional capital from Trails Edge Capital Partners, suggesting a network conducive to strategic partnerships, potential co-development funding, and favorable due diligence environments for partner companies.